You searched for "ophthalmic disease"
Intravitreal injections delivered by ophthalmic clinical nurse specialists
Intravitreal injections of the anti-vascular endothelial growth factor (anti-VEGF) agent ranibizumab, for the treatment of wet age-related macular degeneration (AMD) was approved by National Institute for Health & Care Excellence (NICE) in 2008 [1]. The Manchester Royal Eye Hospital (MREH),...The ophthalmologist’s elbow: a potentially painful point of contact
Three months ago I leant, in the customary manner, on the box of my indirect lens at the slit lamp to examine a patient’s fundus. An acute and severe pain in the tip of my elbow immediately interrupted me. I...Changing the post cataract surgery review pathway – is patient safety compromised?
Cataract surgery continues to be the most commonly performed elective surgical procedure in the UK, with an annual rate of approximately 4150/100,000 people over the age of 65 accounting for a significant proportion of the surgical workload of most ophthalmologists...Fight for Sight to maximise impact by funding solutions-focused research in priority eye conditions
Fight for Sight aims to stop sight loss by funding pioneering research. Rod McNeil takes a look at the Primer Fellowship Awards programme, which provides funding for up to £60,000 for individuals to undertake vision-related research for one year. Among...Reflections on deployment to ICU
Being unexpectedly uprooted from ophthalmology to ICU during the coronavirus pandemic was certainly a challenge, not just clinically, but emotionally and personally. However, it is only through adversary that we learn to appreciate what we have, and there are definitely...Observership in Dar es Salaam
In this report, both authors present their personal experiences of an observership at the Comprehensive Community Based Rehabilitation in Tanzania (CCBRT) Hospital, a large regional teaching hospital located in Dar es Salaam, with a particular focus on resource management, attitudes...
Licence to save: a UK survey of anti-VEGF use for the eye
This comment article highlights the controversy that exists in the choice for anti-VEGF drugs used for treatment of macular oedema and wet age-related macular degeneration (AMD). Two existing licensed drugs for macular oedema are ranibizumab (Lucentis) and aflibercept (Eylea). A...
